Sunday, August 21, 2016

RPI Celebrates Submission of First Marketing Authorisation Application

Our regulatory staff's tireless efforts to prepare our first Marketing Authorisation Application (MAA) were rewarded this month by the acknowledgement of its timely and successful validation. RPI now has full capability to directly submit all eCTD submissions related to the authorisation and maintenance of medicinal products in Europe via EMA’s eSubmission Gateway. The use of the Gateway has significantly improved the EMA’s efficiency in handling the receipt of submissions, making them quickly available within the European Review System.

Find out more about how RPI can support your EMA submissions.

EMA Publishes Final Version of eCTD Module 1 Specification

Starting October 1, 2016, Version 3.0 of the European Union Module 1 electronic Common Technical Document (eCTD) Specification, released by the European Medicines Agency (EMA) will become mandatory.

The guidance document specifies Module 1 of the eCTD and implements several changes from Version 2.0, including:

      additional submission types;
      a new submission unit to further specify regulatory activities;
      a Universal Unique Identifier (UUID) attribute to support automation;
      and various changes to standard terminologies and values.

Committed to staying ahead of the curve, RPI has updated all eCTD tools to support these new technical requirements.

Contact RPI to ensure your UK and EU submissions meet EMA's guidelines.